Conquering Diseases Programs

August 2015

Studies of interest

The Depression Relapse Trial (Docket # H-00007086)
Individuals that are currently suffering from depression are invited to participate in a research study to determine the effectiveness and safety of vortioxetine in preventing relapse in depression for those subjects who respond to treatment with vortioxetine. Study participation will last up to 55 weeks and subjects will receive the study drug vortioxetine. Participants must be: 18 to 75 years of age; suffering from recurrent Major Depressive Disorder; experiencing current symptoms of depression; not be pregnant or have plans to become pregnant. Subjects will receive study drug and study-related care at no cost. Compensation provided. Chelsea Kosma @ 508-856-5312

The Unresolved Depression Study (Docket # H-00005319)
Individuals that are currently suffering from depression are invited to participate in a research study to determine the effectiveness of an investigational drug. Participants will be able to stay on their current medication regimen. Study participation will last up to 60 weeks. Subjects must be: 18 to 70 years of age; suffering from Major Depressive Disorder; currently experiencing depressive symptoms; currently taking an antidepressant; not be pregnant. Participants will receive study drug and study-related care at no cost. Compensation provided. Chelsea Kosma @ 508-856-5312

Do you suffer from chronic pain and opioid addiction (Docket # H-14337)
We are inviting people between the ages of 18-65 who have been diagnosed with both pain and opioid addiction to participate in a 12 week research study. Our intervention may help you reduce drug abuse and manage your pain better. If you are eligible, you will be assigned to a group-based intervention lasting 12 weeks at no cost to you. Participants will also be compensated. For more information, please email opstudy@hotmail.com or call 508-334-2153.

Hepatic Dysfunction, Vitamin D status & Glycemic Control in Diabetes (Docket # H-00002866)
This study is open to enrollment for those 10 to 50 years of age who have type 2 diabetes, low vitamin D levels, and nonalcoholic fatty liver disease. The aim of this study is to determine whether vitamin D supplementation will promote liver health as well as blood sugar control in patients with type 2 diabetes who also have nonalcoholic fatty liver disease. The study will include a MRI scan to determine the amount of fat in the liver. Compensation provided. Study contact: Carol Ciccarelli, RN (508) 856-2828 or carol.ciccarelli@umassmed.edu.

Type 2 Diabetes Study for Children and Adolescents (Docket # H-000005418)
This study looks at how a single dose of an oral medication (Empagliflozin) works in lowering blood sugar in those 10 to less than 18 years of age who have type 2 diabetes. Patients may or may not be currently treated with Metformin and/or long-acting insulin. Study participation will last approximately 3 weeks and require at least 3 visits to the study center with one overnight at local hotel. Hotel lodging and compensation for study participation is provided. Study Contact: Carol Ciccarelli, RN - (508) 856-2828 or carol.ciccarelli@umassmed.edu.

Smoking Study (Docket # H-00007800)
The goal of this study is to find out whether use of a web-based decision support system leads to higher rates of people starting treatment to stop smoking than use of a computerized educational pamphlet. Compensation will be provided. If you are interested and would like more information, please call 508- 856MIND(6463) or email MIND@umassmed.edu.
Participate in the Clinical Research Volunteer Database. The database is used for UMass researchers who are conducting IRB approved studies. (Docket # H-12562)

Parents-looking for a way for your teen/young adult with an intellectual disability to lose weight and be healthy? (Docket # H-00014575)

Health U. is a weight loss research study for overweight teens and young adults ages 15-22 who have an intellectual disability. Eligible participants will take part in a program that includes weekly to biweekly group and individual sessions focusing on losing weight through healthy eating and increasing physical activity in ways that are fun and achievable. Parents receive training on supportive behavioral techniques to encourage their son/daughter to meet nutrition and physical activity goals. Sessions are 90 minutes, highly interactive, and led by nutritionists and lifestyle coaches. Eligibility criteria include, but are not limited to: being a healthy person ages 15-22 with an intellectual disability, meeting criteria for overweight or obesity, medical clearance from a primary health care provider, having at least one parent/guardian who is willing to participate in the study. Health U. is a free and voluntary research study funded by the National Institute of Health (NIH) through the Shriver Center at UMass Medical School. Do you think Health U. is right for you? Please call 774-455-6540 or email healthu@umassmed.edu to find out more information. Qualified participants may be eligible for compensation.

Prelapse Study (Docket # H-00007426)

The goal of this study is to compare the standard treatment for psychosis with a treatment version of the medication aripiprazole that is taken only once each month. Study participants at this study location will receive the care your center usually provides. Those who qualify will receive study-related medical exams, and lab tests at no charge. People in this study will be compensated for their time. In order to participate in the study, individuals must be evaluated by a study doctor and meet certain criteria including, but not limited to: male or female ages 18-35, have a clinical diagnosis of psychosis and up to 5 years of antipsychotic medication exposure. For more information, please contact: 508-856-MIND(6463) or MIND@umassmed.edu.

Tardive Dyskinesia Study (Docket # H-00006334)

We invite those who are experiencing involuntary movements in their face or other parts of their body – and suffer from schizophrenia, schizoaffective disorder – to see if they may qualify for the Kinect 3 Study. The purpose of this clinical research study is to evaluate the effectiveness, safety, and tolerability of an investigational oral medication for tardive dyskinesia. Those who qualify will receive study medication, study-related medical exams, and lab tests at no charge. In order to participate in the study, individuals must be evaluated by a study doctor and meet certain criteria including, but not limited to: male or female aged 18 to 85 years, have clinical diagnosis of schizophrenia or schizoaffective disorder, have a clinical diagnosis of Tardive Dyskinesia (TD). For more information, please contact: 508-856-MIND(6463) or MIND@umassmed.edu.

Exenatide Study (Docket # H-00004119)

Have you been diagnosed with Schizophrenia or Schizoaffective disorder? Are you interested in helping us learn if a drug called Exenatide may improve your memory and thinking? If so, you may be eligible to participate in a research study at UMass Medical School. Studies suggest that Exenatide (an FDA-approved drug) can reduce inflammation, which may protect the brain and improve memory and thinking in individuals with schizophrenia or schizoaffective disorder. Your participation in the study will last 24 weeks (6 months). You will be compensated (paid) for your time. For more information about the study, please call us at 508-856-MIND(6463) or email MIND@umassmed.edu.

Niroprusside Study (Docket # H-00007610)

The goal of this 6-week research study is to assess the effectiveness of Sodium Nitroprusside, an FDA approved drug for management of hypertension, can improve symptoms of schizophrenia. We seek men and women ages 18-60 with a diagnosis of schizophrenia. Participants will be compensated for their time and travel, and all information will be kept private. For more information about the study, please call 508-856-MIND(6463) or email MIND@umassmed.edu.

Did you know that umbilical cord blood has special cells that can be transplanted to help others with blood cell disorders? Our cord blood program, allows new mothers to donate their babies’ cord blood to a public bank, offering those in need a potentially lifesaving match. To date, 17 units have gone for transplant. To learn more, talk with your doctor, visit our website or email.